Did You Lose Money in SVRA? Shareholders Who Lost Money in SVRA Should Contact Robbins LLP for Information About the Savara Inc. Securities Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Allegations - The complaint states that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [2]. - The company misrepresented the timeline for completing the BLA submission, increasing the likelihood of needing additional capital due to delays in regulatory approval [2]. Stock Price Impact - Following the announcement of a refusal to file (RTF) letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by November 7, 2025, although participation is not required to be eligible for recovery [4]. Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].